Old Tiles Decor sold three unapproved 'Wind River' remedies online with drug claims, including treating mpox sores, heart problems and flu.
What happened
FDA reviewed the company's website at www.oldtilesdecor.com on October 11, 2022, and found three "Wind River" products offered for sale with statements that they treat or prevent disease. FDA says these are unapproved new drugs, meaning they are not generally recognized as safe and effective for those uses and have no FDA approval. FDA also says the Skin Comfort Blend and Cayenne Tincture labels lack adequate directions for use, which makes them misbranded.
What FDA found
The three products are 'new drugs' because the website says they treat disease, and they are sold without FDA approval.
FD&C Act section 505(a), 21 U.S.C. 355(a)Website wording shows the products are meant to cure, treat or prevent disease, such as mpox sores, heart problems and cold and flu.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The Skin Comfort Blend and Cayenne Tincture labels do not give adequate directions for use, because their claimed uses need a licensed practitioner's supervision.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5The Elderberry Tincture label gives doses for children and infants even though FDA has not evaluated the product for safety or effectiveness.
Shipping these unapproved and misbranded drugs across state lines is prohibited.
FD&C Act section 301(a) and (d), 21 U.S.C. 331(a) and (d)
What FDA wants
FDA asks the company to stop selling any unapproved products claimed to prevent, treat, diagnose or cure mpox. The company must write to FDA within 15 working days describing the steps taken to fix the problems and prevent repeat violations, or explain why more time is needed and when the work will be done.
Who should pay attention
- online sellers of herbal tinctures and homeopathic remedies
- companies making disease-treatment claims on product webpages or labels
- brands that print child or infant dosing directions on supplement-type products
This is a summary. Read the original letter on fda.gov.